Autres langues Interpace Biosciences, Inc.

Actions

IDXG

US46062X3035

Marché Fermé - OTC Markets Autres places de cotation 21:26:06 06/05/2024			Varia. 5j.	Varia. 1 janv.
1,36 ^USD	-3,55 %		-2,16 %	+25,93 %

07/03	Interpace Biosciences, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
07/03	Interpace Biosciences, Inc. annonce ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	07/03
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results	07/03
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee	12/12
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director	16/11
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results	08/11
Interpace Biosciences, Inc. Enters Amendment to Loan Security Agreement with Broadoak Fund V, L.P	27/10/23
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results	09/08/23
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer	02/08/23
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement	10/07/23
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023	05/06/23
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023	05/06/23
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q1 Revenue $9.8M	12/05/23
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results	12/05/23
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Principal Financial Officer	25/04/23
INTERPACE BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	25/04/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Interpace Biosciences, Inc.

Actions

IDXG

US46062X3035

Autres langues

Filtres